HD17 for Intermediate Stage Hodgkin Lymphoma

Last updated: April 3, 2020
Sponsor: University of Cologne
Overall Status: Completed

Phase

3

Condition

Lymphoma

White Cell Disorders

Marginal Zone Lymphoma

Treatment

N/A

Clinical Study ID

NCT01356680
HD17
  • Ages 18-60
  • All Genders

Study Summary

This study is designed to test the non-inferiority of the experimental arm compared to the standard arm in terms of progression free survival (PFS).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Hodgkin Lymphoma

  • CS I, II with risk factor (stage IIB with risk factor 1 or 2 are not included)

  • large mediastinal mass (>1/3 of maximum transverse thorax diameter)

  • extranodal involvement

  • elevated ESR

  • 3 or more involved nodal areas

  • written informed consent

Exclusion

Exclusion Criteria:

  • Leucocytes <3000/µl

  • Platelets < 100000/µl

  • Hodgkin Lymphoma as composite lymphoma

  • Activity Index (WHO) >2

Study Design

Total Participants: 1100
Study Start date:
January 13, 2012
Estimated Completion Date:
March 23, 2020

Connect with a study center

  • 1st Dept. of Medicine, Cologne University Hospital

    Cologne,
    Germany

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.